ASCO 2024: Updates in Multiple Myeloma : Episode 1
Opinion
Video
Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
Alfred L. Garfall, MD, opens a discussion underscoring the unmet needs in multiple myeloma.
Video content above is prompted by the following:
- Coming into ASCO 2024, what did you consider to be the largest unmet needs in the treatment and management of multiple myeloma (MM)?
- What are the latest trends and innovations you have observed in the treatment and management of MM leading up to and coming out of ASCO 2024?
- How does relapsed/refractory MM (RRMM), particularly after multiple lines of therapy, affect the quality of life of patients and their families?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
December 26th 2024
